Quick Takeaways
- Ayrton Capital LLC filed SCHEDULE 13G for Apimeds Pharmaceuticals US, Inc. Common stock, par value $0.01 per share (APUS).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2025.
Ayrton Capital LLC - 31 Dec 2025 SCHEDULE 13G Report for Apimeds Pharmaceuticals US, Inc. Common stock, par value $0.01 per share (APUS)
- Filing Manager
- Ayrton Capital LLC
- Reporting Manager
- Ayrton Capital LLC
- Symbol
- APUS
- Shares outstanding
- 13,984,194 shares
- Disclosed Ownership
- 1,397,021 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 11 Feb 2026, 09:51:35 UTC
- Date of event
- 31 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Ayrton Capital LLC disclosed 10% ownership in Apimeds Pharmaceuticals US, Inc. Common stock, par value $0.01 per share (APUS) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 11 Feb 2026, 09:51.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Ayrton Capital LLC | 10% | 1,397,021 | 1,397,021 | 0 | /s/ Waqas Khatri | Waqas Khatri / Managing Member | |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 10% | 1,397,021 | 1,397,021 | 0 | /s/ Waqas Khatri | Waqas Khatri / Director | |
| Waqas Khatri | 10% | 1,397,021 | 1,397,021 | 0 | /s/ Waqas Khatri | Waqas Khatri |